Twist Bioscience (TWST)
NASDAQ:TWST
Want to see TWST full AI Analyst Report?
Top Page
Twist Bioscience
(NASDAQ:TWST)
Select Model
Select Model
Rating:63Neutral
Price Target:
$79.00
▲(32.08% Upside)
Action:Reiterated
Date:06/05/26
The score is driven by improving fundamentals and constructive earnings-call guidance (raised revenue outlook and a defined path toward adjusted-EBITDA breakeven), supported by a strong technical uptrend. These are tempered by continued losses and cash burn, and valuation is weakened by the lack of profitability (negative P/E) and no dividend support.
Positive Factors
Sustained revenue scaling
Twist has shown durable top-line momentum with multi-year scaling (TTM revenue ~ $409M vs. ~$132M in 2021) and 13 straight quarters of sequential growth. Persistent revenue expansion signals broadening customer adoption, improving commercial penetration and platform stickiness that support multi‑quarter cash flow improvement prospects.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow implies continued reliance on existing cash, financing or cost reductions to fund growth. Until operating cash flow turns sustainably positive, balance sheet flexibility and the firm's ability to self‑fund expansion remains constrained, elevating execution risk over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue scaling
Twist has shown durable top-line momentum with multi-year scaling (TTM revenue ~ $409M vs. ~$132M in 2021) and 13 straight quarters of sequential growth. Persistent revenue expansion signals broadening customer adoption, improving commercial penetration and platform stickiness that support multi‑quarter cash flow improvement prospects.
Read all positive factors
Twist Bioscience (TWST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.60B
Dividend YieldN/A
Average Volume (3M)1.53M
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue Growth17.77%
EPS Growth59.40%
CountryUS
Employees923
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.32
Shares Outstanding62,271,313
10 Day Avg. Volume1,687,491
30 Day Avg. Volume1,528,823
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue10.10
Enterprise Value/Gross Profit19.40
Enterprise Value/Ebitda-71.06
Forecast
1Y Price Target
$64.00Price Target Upside7.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.05
Revenue Forecast (FY)$446.65M
Twist Bioscience Business Overview & Revenue Model
Company Description
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic D...
How the Company Makes Money
Twist Bioscience primarily generates revenue by selling synthetic biology research products and related services to life-science and applied-market customers. Key revenue streams include: (1) Synthetic DNA products: Sales of custom DNA constructs ...
Twist Bioscience Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and commercial story: strong top-line growth (19% YoY), robust outperformance in therapeutics (55% YoY), gross margin above 50%, strategic partnerships (AWS) and an explicit path to adjusted EBITDA breakeven in Q4 FY2026. Offsetting these positives are ongoing adjusted EBITDA losses, higher operating expenses tied to strategic investments, a reduction in cash balances, a pending litigation settlement and certain end-market pressures (academic funding headwinds and some segment declines). Management provided clear remediation steps (cost reductions, targeted automation, acceptance-rate improvements) and raised full-year guidance, indicating confidence in execution.Positive Updates
Consistent Revenue Growth
Total revenue of $110.7M in Q2 FY2026, up 19.3% year-over-year and marking the 13th consecutive quarter of sequential revenue growth.
Negative Updates
Adjusted EBITDA Still Negative
Adjusted EBITDA loss of approximately $13.3M in Q2, although improved ~$1.5M year-over-year; company remains on a path to breakeven but is not yet profitable on an adjusted EBITDA basis.
Read all updates
Q2-2026 Updates
Positive
Negative
Consistent Revenue Growth
Total revenue of $110.7M in Q2 FY2026, up 19.3% year-over-year and marking the 13th consecutive quarter of sequential revenue growth.
Read all positive updates
Company Guidance
Twist guided fiscal 2026 revenue of $442–447 million (growth ~17–19%) and Q3 revenue of $114–115 million (≈19% YoY at the midpoint), said NGS will drive H2 sequential growth and return to ~20% growth by Q4, and reiterated a target of adjusted‑EBITDA breakeven in Q4 FY2026. They expect full‑year gross margin of ~52%+ (Q2 was 51.6%), cited a 75–80% average incremental gross‑margin drop‑through on new revenue, and plan approximately $6 million of sequential OpEx improvement in Q4 from cost actions; Q2 adjusted EBITDA was a loss of ~$13.3 million (an improvement of ~$1.5M YoY). Cash was $171.7 million at quarter end (versus $197.9M at 12/31/25); Q2 used $17.6M in operating cash, spent $7.9M in CapEx and $5.0M on the Invenra license, and recorded $7.2M of litigation settlement costs as part of a ~$17.1M class‑action resolution expected to be largely insurance‑covered.Twist Bioscience Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
74
Positive
Cash Flow
43
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 409.48M | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M |
| Gross Profit | 213.23M | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M |
| EBITDA | -58.23M | -52.10M | -176.71M | -174.15M | -211.68M | -143.91M |
| Net Income | -81.28M | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M |
Balance Sheet | ||||||
| Total Assets | 676.21M | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M |
| Cash, Cash Equivalents and Short-Term Investments | 171.67M | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M |
| Total Debt | 95.84M | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M |
| Total Liabilities | 221.12M | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M |
| Stockholders Equity | 455.09M | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M |
Cash Flow | ||||||
| Free Cash Flow | -95.14M | -75.63M | -69.17M | -170.25M | -226.24M | -139.31M |
| Operating Cash Flow | -55.59M | -47.63M | -64.09M | -142.47M | -124.39M | -112.24M |
| Investing Cash Flow | -44.44M | -24.76M | -3.07M | 50.61M | -232.93M | 156.16M |
| Financing Cash Flow | 11.84M | 28.54M | 6.89M | 911.00K | 270.53M | 329.18M |
Twist Bioscience Technical Analysis
Positive
59.81
Price Trends
57.26
Positive
51.68
Positive
40.93
Positive
Market Momentum
4.30
Negative
61.88
Neutral
70.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Positive. The current price of 59.81 is below the 20-day moving average (MA) of 60.82, above the 50-day MA of 57.26, and above the 200-day MA of 40.93, indicating a bullish trend. The MACD of 4.30 indicates Negative momentum. The RSI at 61.88 is Neutral, neither overbought nor oversold. The STOCH value of 70.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TWST.
Twist Bioscience Risk Analysis
Twist Bioscience disclosed 61 risk factors in its most recent earnings report. Twist Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Twist Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.19B | -138.91 | -2.61% | ― | 19.17% | -111.99% | |
63 Neutral | $4.60B | -52.55 | -17.46% | ― | 17.77% | 59.40% | |
59 Neutral | $2.86B | -6.17 | -16.42% | ― | 19.44% | 82.94% | |
57 Neutral | $1.47B | -2.84 | -11.82% | ― | 10.95% | -26.52% | |
54 Neutral | $553.81M | -8.01 | -6.70% | ― | 9.54% | -79.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $442.96M | -1.07 | -109.09% | ― | -0.28% | -286.80% |
* Healthcare Sector Average
TWST
Twist Bioscience
69.22
37.65
119.26%
MYGN
Myriad Genetics
4.57
-0.52
-10.22%
NEO
NeoGenomics
10.90
3.48
46.90%
CDNA
CareDx
22.25
2.73
13.99%
FLGT
Fulgent Genetics
19.15
-2.28
-10.64%
GRAL
GRAIL Inc
59.98
21.62
56.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.